IP Library Granted Patent US 11,992,556
Granted Patent B2
US 11,992,556 · App. 17/319,655 · Granted May 28, 2024

Pharmaceutical aerosol product for administration by oral or nasal inhalation

Inventors: Helgert Müller (Radolfzell, DE); Renate Engelstätter (Allensbach, DE); Ulrich Bildmann (Hilzingen, DE); Andrea Bauer (North Reading, MA); Paul McGlynn (Northborough, MA)
Assignee: Covis Pharma GmbH
A61K9/124A61K9/008A61K31/58A61M11/04A61M15/0001A61M15/0065A61M15/009
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,992,556
App. No.
17/319,655
Granted
May 28, 2024
Kind
B2
Abstract

This invention relates to a pharmaceutical aerosol product suitable for administration by oral or nasal inhalation and its use in the treatment of respiratory diseases, in particular in the treatment of children. The aerosol composition comprises ciclesonide, ethanol and either 1, 1, 1, 2-tetrafluoroethane, or 1, 1, 1, 2, 3, 3, 3-heptafluoropropane.

Claims (18)

1. A method for preparing a pharmaceutical composition, the method comprising:

combining:

(a) ciclesonide,

(b) a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof, and

(c) ethanol in an amount effective to solubilize the ciclesonide and

(d) optionally a surfactant,

wherein the concentration of ciclesonide in the composition is from 0.1 to 0.8 mg per ml, wherein the pharmaceutical composition is contained in an aerosol canister equipped with a metering valve.

2. The method of claim 1 , wherein the ciclesonide is solubilized by the ethanol.

3. The method of claim 1 , wherein the concentration of ciclesonide in the composition is from 0.4 to 0.5 mg per ml.

4. The method of claim 1 , wherein the concentration of ethanol in the composition is from 30 to 300 mg per ml.

5. The method of claim 1 , wherein the propellant is 1,1,1,2-tetrafluoroethane.

6. The method of claim 1 , wherein the propellant is 1,1,1,2,3,3,3-heptafluoropropane.

7. The method of claim 1 , wherein the concentration of propellant in the composition is from 1000 to 1400 mg per ml.

8. The method of claim 1 , wherein the combining comprises mixing the ciclesonide and ethanol to form a concentrate, and then adding and mixing the propellant to the concentrate.

9. The method of claim 1 , wherein the combining comprises mixing the ciclesonide and ethanol to form a concentrate.

10. The method of claim 9 , further comprising adding the concentrate into the aerosol canister.

11. The method of claim 10 , further comprising adding the propellant to the aerosol vial while under pressure.

12. The method of claim 1 , wherein the ciclesonide is the sole drug in the pharmaceutical composition.

Assignments (9)
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded May 27, 2025
From: COVIS PHARMA GBMH
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 071409/0368 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Mar 17, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: COVIS PHARMA GMBH
Reel/Frame 070537/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2023
From: TAKEDA GMBH
To: ASTRAZENECA AB
Reel/Frame 063898/0011 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2023
From: MULLER, HELGERT; ENGELSTATTER, RENATE; BILDMANN, ULRICH; BAUER, ANDREA; MCGLYNN, PAUL
To: TAKEDA GMBH
Reel/Frame 063897/0724 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2023
From: ASTRAZENECA AB
To: COVIS PHARMA B.V.
Reel/Frame 063930/0881 →
BUSINESS TRANSFER AND CONTRIBUTION AGREEMENT Recorded Jun 8, 2023
From: COVIS PHARMA B.V.
To: COVIS PHARMA GMBH
Reel/Frame 063939/0080 →
RELEASE OF SECURITY INTEREST Recorded Jun 2, 2023
From: BARCLAYS BANK PLC
To: COVIS PHARMA GMBH
Reel/Frame 063841/0208 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (SECOND LIEN) Recorded Feb 18, 2022
From: COVIS PHARMA GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 059232/0514 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (FIRST LIEN) Recorded Jan 4, 2022
From: COVIS PHARMA GMBH
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 058640/0787 →